Company Overview

Opthea Limited is a clinical-stage biopharmaceutical company focused on the development of novel therapies for retinal vascular diseases, particularly wet age-related macular degeneration (wet AMD). The company operates within the biotechnology and pharmaceutical industries and has no approved commercial products, deriving its value primarily from research and development activities. Its core product candidate has been sozinibercept (OPT-302), a biologic designed to be used in combination with standard anti-VEGF-A therapies to potentially improve visual outcomes for patients with wet AMD.

Opthea was founded in 2004 in Australia and has evolved from an early-stage ophthalmology research company into a late-stage clinical developer. The company gained international visibility through the advancement of OPT-302 into global Phase 3 clinical trials. However, in late 2023, Opthea announced that its Phase 3 trials did not meet primary endpoints, materially impacting its strategic and financial position. The company has historically positioned itself around a differentiated mechanism of action targeting VEGF-C and VEGF-D pathways, which was intended to complement existing therapies rather than compete directly with them.

Business Operations

Opthea operates as a single-segment business focused on ophthalmic drug development, with activities centered on clinical research, regulatory engagement, and corporate management. The company does not generate product revenue and has historically relied on equity financing and capital markets to fund operations. Its primary asset has been the intellectual property and clinical data related to sozinibercept (OPT-302).

Operationally, Opthea conducts research and development through a combination of internal management and outsourced clinical trial execution, including contract research organizations. The company has maintained operations in both Australia and the United States, with its U.S. subsidiary, Opthea, Inc., supporting clinical development and regulatory interactions. Data regarding active partnerships or ongoing joint ventures following the Phase 3 trial outcomes is inconclusive based on available public sources.

Strategic Position & Investments

Opthea’s strategic direction has historically been centered on advancing OPT-302 through late-stage development and seeking regulatory approval in major markets. Prior to the Phase 3 trial outcomes, the company pursued a strategy of combination therapy positioning, aiming to integrate its drug with existing anti-VEGF standards of care. Following the unsuccessful trial results, Opthea announced a strategic review to evaluate future options, including potential restructuring, asset monetization, or alternative development pathways.

The company has not disclosed significant acquisitions or a diversified portfolio of subsidiaries beyond Opthea, Inc. Public disclosures indicate that capital allocation has been primarily directed toward clinical trials and supporting infrastructure. Information regarding new investments, alternative pipeline assets, or emerging technology initiatives after 2023 is inconclusive based on available public sources.

Geographic Footprint

Opthea is headquartered in Australia, with a significant operational presence in the United States, reflecting the global nature of its clinical development programs. The company has conducted multinational clinical trials across North America, Europe, and the Asia-Pacific region, engaging clinical sites in multiple countries to support regulatory submissions.

While Opthea does not maintain manufacturing or commercial infrastructure, its international footprint has been shaped by regulatory strategy and clinical trial requirements rather than sales operations. The company’s American Depositary Receipt (ADR) listing under OPTEY reflects its engagement with U.S. capital markets, complementing its primary Australian Securities Exchange listing.

Leadership & Governance

Opthea has been led by a board and executive team with experience in biotechnology, pharmaceuticals, and capital markets. The company’s leadership has emphasized scientific rigor, unmet medical need in retinal disease, and disciplined capital management, particularly following the reassessment of strategy after clinical setbacks.

Key executives and directors include:

• Dr. Frederic Guerard – Chief Executive Officer
• Brian Jamieson – Chairman
• Greg Weaver – Chief Financial Officer
• Dr. Robyn Guymer – Non-Executive Director

Certain executive roles and responsibilities have evolved following the 2023 clinical trial outcomes. Where discrepancies exist across public disclosures regarding current leadership status, data is inconclusive based on available public sources.